Our position on working with the pharmaceutical sector

30 Jun 2016

Bloodwise position on working with the pharmaceutical sector

The purpose of this policy is to provide clear principles and guidance about how Bloodwise works with pharmaceutical companies. Such partnerships enable us to achieve the charity’s mission without compromising our integrity.  This policy exists to ensure our work with pharmaceutical firms does not affect our ability to offer independent and unbiased patient information, or influence our campaigning, research or fundraising activities.

Bloodwise recognises that working with pharmaceutical companies that manufacture and market drugs and treatments gives Bloodwise important knowledge and expertise.  Such companies are also willing to sponsor and fund certain activities undertaken by Bloodwise. However, pharmaceutical companies are not charitable organisations and Bloodwise takes particular care in how it works with them.

Below are the principles which Bloodwise will adhere to when entering into partnerships with pharmaceutical firms and ensures that all partnerships are consistent with our organisational aims.

These are as follows:

  1. All partnerships will be based on the principles of integrity and openness and will bring benefit to Bloodwise through funding or through supporting Bloodwise to achieve its mission.
  2. Any joint activity must be fit within Bloodwise’s mission and strategic aims 
  3. All partnerships between pharmaceutical companies and Bloodwise including employee fundraising relationships will be subject to a full risk assessment and approval by the relevant Executive Team members.
  4. Any partnership entered into will not compromise the independent status of Bloodwise. When working with partners with a commercial interest in blood cancer we will, where linked to political or campaigning activities, seek to work with a minimum of two partners in order to maintain independence and impartiality.
  5. We will ensure that our editorial independence is maintained so that we are free to comment both positively and negatively about pharmaceutical companies and their products
  6. Bloodwise welcomes opportunities to raise funds and awareness through cause related marketing and sponsorship. However, Bloodwise will not directly endorse any third party, its products or services.
  7. Bloodwise will work with members of the pharmaceutical industry to share knowledge and expertise.  This may involve the participation in pharmaceutical industry organised events such as:
  • Private or public meetings
  • Training events
  • Advisory board meetings
  • Market research events
  1. No commercial partnership will be entered into with a company whose product or service is considered to be detrimental to people living with blood cancer, or any product or service with unsupported claims of positive benefits to those with blood cancer. All partnerships with products and services with specific links to blood cancer will require approval by the Director of Research and Director of Patient Experience.  
  2. Partnerships with pharmaceutical companies will not compromise Bloodwise’s independent status and will comply with the ABPI Code of Practice for the Pharmaceutical Industry.
  3. Bloodwise will not accept support for activities which lie outside our objectives. Where possible we favour the use of a funding consortia based on two or more pharmaceutical companies working together. However, we will enter into strategic partnerships with individual companies if it is deemed to be in the best interest of those affected by blood cancer.
  4. Bloodwise will not undertake any joint work with, or accept funding from, a pharmaceutical company where promotion of a specific drug is required or demanded by the company (either explicitly or implicitly).
  5. There may be occasions where we will campaign for equitable access to a treatment. Under no circumstances will we accept funding from pharmaceutical companies to support campaigning activity for access to specific treatments. In the instance of campaigning for access to a drug made by a company that Bloodwise has received funding from currently or in the past for separate projects, we will ensure that all funding is declared as requested on official documentation provided to regulators, and make clear that funding for separate projects has no impact on whether we campaign for access to a specific treatment or not.
  6. Any funding or joint activity must be compliant with the conditions of the ABPI Code of Practice for the Pharmaceutical Industry. Where a company is not a member of the ABPI we will require written assurances that any partnership work or support will be conducted to the ABPI Code of Practice.